Surgical Experience with Ulipristal Acetate or Gonadotropin Releasing Hormone Agonists for Uterine Fibroids

Wais, Marta; Lee, S; Liu, G; Pham, Alice; Tai, Melissa; Murji, Ally

doi:10.1016/j.jmig.2016.08.247

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There was a decrease in overall operating time, but suturing time was not different between the 2 groups. 53 Aref-Adib et al 54 reported on the lack of surgical planes when UPA was used prior to laparoscopic myomectomy and this finding was echoed by Wais et al 55 in a multicentre prospective trial where they found a significant difference in the difficulty of separation of fibroids from the myometrium and denucleation in patients pre-treated with UPA compared to no pre-treatment, but apart from the nuances, there was no significant difference in operation outcome. Although theoretically possible to alter the route of hysterectomy with a decrease in uterine size following the administration of UPA, there have been reports of increase in size of fibroids and cystic degeneration following UPA use.…”

Section: Modern Management Of Fibroidsmentioning

confidence: 98%

Is ulipristal acetate the new drug of choice for the medical management of uterine fibroids? Res ipsa loquitur?

Odejinmi

Oliver

Mallick

2017

Womens Health (Lond Engl)

View full text Add to dashboard Cite

Ulipristal acetate (Esmya © ) has been hailed the new wonder drug with regard to the medical management of uterine fibroids, and many postulate that it will remove the need for surgical treatment in the future. While the results from the PEARL studies are certainly promising and its amenorrhoeic rates and reduction in fibroid size are unquestionable, there is still a paucity of data with regard to its long-term effects, the effects on its usage prior to surgery and its variable efficacy in different ethnic populations. To facilitate our knowledge further, independent studies with clear outcome measures evaluating the long-term effects of the drug in a wider, more representative, ethnic minority population as well as assessing its true cost-effectiveness compared to surgery are needed. The aim of this article is to review the historical aspects with regard to the management of uterine fibroids to gain an understanding of where we are now and to evaluate the wider use of ulipristal acetate, both its benefits and limitations and postulate where to go in the future in order to allow our women to make safe and informed choices regarding their treatment options.

show abstract

Section: Modern Management Of Fibroidsmentioning

confidence: 98%